What is ABBV's House Rating?

ABBV scores 56 out of 100 (grade C) as of 2026-10-16, ranking #51 of 150 Health Care stocks we cover.

What do analysts say about ABBV?

ThetaGrade's analyst-sentiment pillar for ABBV scores 83/100 against its sector peers, which we read as positive. This is our own derived score; we do not republish individual analyst ratings, counts or targets.

When does ABBV report earnings next?

We do not have a reliable estimate for ABBV's next earnings date (irregular SEC filing history); a rough window is 2026-07-30 to 2027-01-30. Check the company's investor-relations page.

ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.

ABBV AbbVie

Health Care · Biotechnology · close $285.42 (2026-10-16) · latest quarter in EDGAR: 2026-06-30

#51/150 in sector · #385/964 overall

AbbVie (ABBV) has a ThetaGrade House Rating of 56/100 (grade C), ranking #51 of 150 in Health Care. Its strongest pillars are analyst sentiment (83) and profitability (75); its weakest is valuation (21). TTM revenue growth is 10.4% and operating margin 26.2%.

Data as of 2026-10-16.

Analyst sentiment

weight 7.5% · 83

Consensus score (1–5) (3.8%)	derived	69
90-day net rating shift (3.8%)	derived	70

Growth

weight 30.83% · 63

Revenue growth YoY (TTM) (12.3%)	10.4%	53
EPS growth YoY (TTM) (12.3%)	68.6%	86
Revenue acceleration (6.2%)	-2.3%	37

Profitability

weight 18.5% · 75

Operating margin (9.9%)	26.2%	84
4Q gross-margin change (8.6%)	0.5%	64

Balance sheet

weight 18.5% · 23

Net debt / EBITDA (9.9%)	3.29×	22
Current ratio (4.9%)	0.81	2
Interest coverage (3.7%)	5.83×	56

Cash flow

weight 12.33% · 75

FCF margin (6.2%)	29.1%	91
FCF yield (6.2%)	3.5%	58

Valuation

weight 12.33% · 21

P/E (inverted) (6.2%)	80.63×	13
EV/Sales (inverted) (6.2%)	8.73×	29

Technicals (EOD)

RSI(14)	71.1
EMA 9 / 21	277.92 / 271.54
200-day SMA	233.95
Volume vs 20d avg	1.16×
20-day return	8.1%

Exit-rule monitor

EXITRating break: House Rating below 60

Data source per metric (SEC XBRL tag or derivation): Revenue: Revenues · Gross profit: Revenue − CostOfGoodsAndServicesSold · Operating income: OperatingIncomeLoss · Interest expense: InterestExpense · D&A: Depreciation · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).

Get rating changes like ABBV's in the free Daily Brief

The market’s key events and signals, digested before the open.

✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
✓ OPEX, FOMC, CPI and jobs-day reminders

Free. Want more? See Premium (waitlist).

FAQ

What is ABBV's House Rating?: ABBV scores 56 out of 100 (grade C) as of 2026-10-16, ranking #51 of 150 Health Care stocks we cover.
What do analysts say about ABBV?: ThetaGrade's analyst-sentiment pillar for ABBV scores 83/100 against its sector peers, which we read as positive. This is our own derived score; we do not republish individual analyst ratings, counts or targets.
When does ABBV report earnings next?: We do not have a reliable estimate for ABBV's next earnings date (irregular SEC filing history); a rough window is 2026-07-30 to 2027-01-30. Check the company's investor-relations page.
Is ABBV a buy?: ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.

Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology